It's been a pretty great week for AngioDynamics, Inc. (NASDAQ:ANGO) shareholders, with its shares surging 13% to US$6.95 in the week since its latest full-year results. It looks like a positive result overall, with revenues of US$304m beating forecasts by 3.8%. Statutory losses of US$4.59 per share were roughly in line with what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Taking into account the latest results, the current consensus, from the three analysts covering AngioDynamics, is for revenues of US$284.4m in 2025. This implies a perceptible 6.4% reduction in AngioDynamics' revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 82% to US$0.81. Before this latest report, the consensus had been expecting revenues of US$287.2m and US$1.19 per share in losses. Although the revenue estimates have not really changed AngioDynamics'future looks a little different to the past, with a considerable decrease in the loss per share forecasts in particular.

The average price target held steady at US$13.33, seeming to indicate that business is performing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values AngioDynamics at US$14.00 per share, while the most bearish prices it at US$13.00. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the AngioDynamics' past performance and to peers in the same industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 6.4% by the end of 2025. This indicates a significant reduction from annual growth of 5.0% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 8.2% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - AngioDynamics is expected to lag the wider industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$13.33, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for AngioDynamics going out to 2027, and you can see them free on our platform here.

It is also worth noting that we have found 2 warning signs for AngioDynamics that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com